Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration

Clinical Pharmacokinetics

Volumn 53, Issue 10, 2014, Pages 907-918

  Othman, Ahmed A ^a,b   Tran, Jonathan Q ^c   Tang, Meina T ^a,d   Dutta, Sandeep ^a  

^a ABBVIE INC   (United States)

^b CAIRO UNIVERSITY   (Egypt)

^c BIOGEN   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DACLIZUMAB; PLACEBO; DACLIZUMAB HYP; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; APPENDICITIS; AREA UNDER THE CURVE; ARTICLE; ATELECTASIS; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DERMATITIS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELIMINATION HALF-LIFE; FATIGUE; FEMALE; FOLLOW UP; HALF LIFE TIME; HEADACHE; HIGH YIELD PROCESS; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; LIMIT OF QUANTITATION; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POPULATION MODEL; PROCESS DESIGN; PROCESS DEVELOPMENT; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRUS PNEUMONIA; VOLUME OF DISTRIBUTION; ADOLESCENT; BIOLOGICAL MODEL; CLINICAL TRIAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROTEIN ENGINEERING; SUBCUTANEOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROTEIN ENGINEERING; YOUNG ADULT;

EID: 84918781029     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0159-9     Document Type: Article

References (22)

1. Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453–79. doi:10.1146/annurev.immunol.26.021607.090357.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221–31. doi:10.1016/S0140-6736(02)08220-X.
3. Matesanz F, Fedetz M, Collado-Romero M, Fernandez O, Guerrero M, Delgado C, et al. Allelic expression and interleukin-2 polymorphisms in multiple sclerosis. J Neuroimmunol. 2001;119(1) (pii: 101–5 S0165-5728(01)00354-X).
4. Svejgaard A. The immunogenetics of multiple sclerosis. Immunogenetics. 2008;60(6):275–86. doi:10.1007/s00251-008-0295-1.
5. McDyer JF, Li Z, John S, Yu X, Wu CY, Ragheb JA. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production. J Immunol. 2002;169(5):2736–46.
6. Woo J, Tsao T, Zhao V, McClellan M, Li J, Keller S, et al. Differential effect of daclizumab, a SMART(TM) humanized anti-CD25 antibody, on resting and activated T-cells [abstract]. Clin Immunol. 2002;103(3 Suppl):S50. doi:10.1006/clim.2002.5242.
7. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006;103(15):5941–6. doi:10.1073/pnas.0601335103.
8. Perry JS, Han S, Xu Q, Herman ML, Kennedy LB, Csako G, et al. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med. 2012;4(145):145ra06. doi:10.1126/scitranslmed.3004140.
9. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol. 2010;9(4):381–90. doi:10.1016/S1474-4422(10)70033-8.
10. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9884):2167–75. doi:10.1016/S0140-6736(12)62190-4.
11. Biogen Idec. Efficacy and safety of daclizumab high yield process versus interferon β 1a in patients with relapsing-remitting multiple sclerosis (DECIDE). ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US) [ClinicalTrials.gov identifier: NCT01064401]. http://clinicaltrials.gov/ct2/show/NCT01064401. Accessed 20 Jan 2014.
12. ® (daclizumab) US product label. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113486.pdf. Accessed 8 May 2014.
13. Data on file (2005), AbbVie.
14. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annu Rev Pharmacol Toxicol. 1992;32:185–209. doi:10.1146/annurev.pa.32.040192.001153.
15. Beal SL, Sheiner LB. NONMEM users guide, Part V. San Francisco: Division of Clinical Pharmacology, University of California; 1979–1992.
16. Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24(12):2187–97. doi:10.1007/s11095-007-9361-x.
17. Dutta S, Reed RC. Functional half-life is a meaningful descriptor of steady-state pharmacokinetics of an extended-release formulation of a rapidly cleared drug: as shown by once-daily divalproex-ER. Clin Drug Investig. 2006;26(12):681–90. doi:10.2165/00044011-200626120-00002.
18. Boxenbaum H, Battle M. Effective half-life in clinical pharmacology. J Clin Pharmacol. 1995;35(8):763–6.
19. Pescovitz MD, Knechtle S, Alexander SR, Colombani P, Nevins T, Nieforth K, et al. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatr Transpl. 2008;12(4):447–55. doi:10.1111/j.1399-3046.2007.00830.x.
20. Koch M, Niemeyer G, Patel I, Light S, Nashan B. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation. 2002;73(10):1640–6.
21. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transpl. 2003;3(1):50–2. doi:10.1034/j.1600-6143.2003.30109.x.
22. Vincenti F, Lantz M, Birnbaum J, Garovoy M, Mould D, Hakimi J, et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation. 1997;63(1):33–8.